A defect in TGF-␤ signaling is observed in HTLV-I-infected cells obtained from HAM/TSP patients. This is associated with low levels of Foxp3 expression and with disruption of both T regulatory and T effectors functions. Disruption of TGF-␤ signaling is therefore likely to participate in HAM/TSP pathogenesis.
H TLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) develops in a subset of human T lymphotropic virus type I (HTLV-I)-infected individuals. 1 Its evolution is chronic and progressive, without remission. 2 Recently, a study using a histone deacetylase inhibitor reported, for the first time, a spectacular decline in the HTLV-I proviral load in a series of HAM/TSP patients. 3 Unfortunately, clinical benefits were limited.
Although it is known that Tax proviral load and a dysregulated immune response play major roles in disease progression, HAM/TSP pathogenesis is still poorly understood. To explain the role of HTLV-I in the progression of HAM/ TSP, 3 mechanisms have been proposed 1 : an antiviral attack mediated by cytotoxic T lymphocytes, 2 an autoimmune response, 3 or bystander damage due to cytokines such as TNF-␣. 4 CD4 ϩ /CD25 ϩ T cells expressing the forkhead transcription factor Foxp3 are defined as regulatory T cells (Tregs). These cells play a key role in the maintenance of immune system homeostasis. As shown by 2 recent reports, Tregs from HAM/TSP patients express low levels of Foxp3 and have impaired suppressor functions, 5,6 while another apparently conflicting set of findings shows a strong negative correlation between the frequency of circulating CD4 ϩ Foxp3 ϩ Tax Ϫ Tregs and the rate of cytotoxic T lymphocyte-mediated lysis of autologous HTLV-I-infected cells. 7 Prior to the findings reported by Grant and colleagues in this issue of Blood, the mechanism leading to defective Treg function was not clear.
Because TGF-␤ signaling is involved in Foxp3 expression and Treg suppressor function, Grant and colleagues investigated whether TGF-␤ signaling was affected in CD4 ϩ cells isolated from HAM/TSP patients. They first demonstrated that the levels of TGF-␤ receptor II (TGF-␤RII) were low in these cells, and that an inverse correlation between TGF-␤RII expression and Tax pro-viral load could be measured. Interestingly, the capability of TGF-␤ to induce Foxp3 expression in CD ϩ /CD25 Ϫ Foxp3 Ϫ cells isolated from HAM/TSP patients was also weakened. Then, they showed that knocking out the expression of Smad4, a TGF-inducible gene, caused a massive reduction in Foxp3 levels, confirming that integrity of the TGF-␤ signaling pathway must be maintained for normal Foxp3 expression. However, whether the Foxp3 promoter contains Smad4 binding sites or not, and how exactly TGF-␤ signaling is impaired by HTLV-I, remains to be determined. Is the mechanism similar to that previously described for HTLV-I adult T-cell leukemia/lymphoma cells? 8 Finally, the authors established that CD4 ϩ /CD25 ϩ T cells isolated from a series of HAM/TSP patients failed to suppress the proliferation of CD4 ϩ /CD25 Ϫ T cells isolated from the same individuals. This latter population was also resistant to suppression mediated by Treg cells obtained from normal donors.
Altogether, these results undoubtedly show that because of a defect in TGF-␤ signaling, Foxp3 expression is decreased, and both Treg and effector T-cell functions are impaired in HAM/TSP patients. It is tempting to speculate that these deficiencies play key roles in the progression of the disease.
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Follicular lymphomas and histiocytic/dendritic neoplasms related? ----------------------------------------------------------------------------------------------------------------Jonathan Said UNIVERSITY OF CALIFORNIA LOS ANGELES MEDICAL CENTER
In this issue of Blood, Feldman and colleagues provide convincing evidence of a clonal relationship between follicular lymphoma and H/DC sarcoma, suggesting plasticity between these apparently disparate lineages with implications for transformation events in malignant lymphomas.
T he rarity of dendritic-cell tumors and the little that is known about their pathogenesis makes them a fascinating subject.The availability of new methodologies to confirm dendritic-cell lineage and awareness of the broadening morphologic spectrum have resulted in wider recognition of this tumor. There are no known etiologic 5418
